3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
1
Glioma
1
Glioblastoma
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
39
Radiotherapy
18
Lomustine
12
Bevacizumab
11
Carmustine
8
Radiation
7
Procarbazine
4
Magnetic Resonance Spectroscopy
4
Surgical Procedures, Operative
3
pembrolizumab
2
depatuxizumab mafodotin
2
Tf-CRM107
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Drug Therapy
2
Dihematoporphyrin Ether
2
DNA Methylation
2
Carboplatin
2
ABT-414
2
trans-sodium crocetinate
1
tofacitinib
1
sargramostim
1
rindopepimut
1
niraparib
1
marizomib
1
enzastaurin
1
edotecarin
1
contrast agent BR1
1
cediranib
1
carmustine, poliferprosan 20 drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Glioblastoma
×
Trabedersen
×
Clear all
NCT00761280
2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3
Terminated
27 enrolled
28 charts